Valuation: Forte Biosciences, Inc.

Market Cap 46Cr 40Cr 37Cr 35Cr 65Cr 4.31TCr 66Cr 443.94Cr 171.95Cr 2.13TCr 171.69Cr 167.93Cr 7.39TCr P/E 2026 *
-4.56x
P/E 2027 * -4.4x
Enterprise Value 46Cr 40Cr 37Cr 35Cr 65Cr 4.31TCr 66Cr 443.94Cr 171.95Cr 2.13TCr 171.69Cr 167.93Cr 7.39TCr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.85%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Forte Biosciences, Inc.

1 day+0.92%
1 week+4.82%
Current month-1.89%
1 month-13.34%
3 months-29.08%
6 months-31.81%
Current year-31.39%
1 week 16.89
Extreme 16.89
19.48
1 month 15.51
Extreme 15.51
23.07
Current year 15.51
Extreme 15.51
35.8
1 year 9.1
Extreme 9.1
35.8
3 years 4.11
Extreme 4.11
35.8
5 years 4.11
Extreme 4.11
921.25
10 years 4.11
Extreme 4.11
1,349.75
Manager TitleAgeSince
Chief Executive Officer 55 01/01/2018
Director of Finance/CFO 59 01/03/2020
Chief Operating Officer - 01/10/2020
Director TitleAgeSince
Chairman 55 -
Director/Board Member 58 01/06/2020
Director/Board Member 79 16/03/2022
Date Insider Type Main position Quantity % Market Cap.
16/06Free

Chief Financial Officer

22,000 0.1074%
16/06Free

Chief Executive Officer

5,00,000 2.4415%
29/05Free

Director

18,353 0.0896%
Change 5-day change 1-year change 3-year change Capi.($)
+0.92%+4.82%+76.68%-27.34% 46Cr
+4.43%+2.49%+61.83%+115.25% 5.53TCr
+1.58%+14.12%+72.87%+85.18% 5.19TCr
-0.23%-0.98%-14.12%-16.00% 2.28TCr
+0.98%+9.05%-0.36%+423.40% 2.26TCr
+0.18%+7.74%+32.48%-13.86% 1.74TCr
+0.88%+5.78%+30.82%-34.26% 1.61TCr
+3.02%+12.74%+143.33%+308.04% 1.4TCr
+0.68%+2.54%+22.28%+168.03% 1.34TCr
+1.50%+6.73%+28.86% - 1.23TCr
Average +1.38%+5.72%+45.47%+112.05% 2.26TCr
Weighted average by Cap. +1.90%+6.54%+46.97%+120.46%

Financials

2026 *2027 *
Net sales - -
Net income -9.55Cr -8.39Cr -7.73Cr -7.23Cr -14Cr -901.5Cr -14Cr -93Cr -36Cr -444.39Cr -36Cr -35Cr -1.54TCr -13Cr -11Cr -11Cr -9.87Cr -19Cr -1.23TCr -19Cr -126.65Cr -49Cr -606.71Cr -49Cr -48Cr -2.11TCr
Net Debt - -
Logo Forte Biosciences, Inc.
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Employees
22
Date Price Change Volume
25/26/25 $18.71 +0.92% 1,86,507
24/26/24 $18.54 +2.15% 2,17,126
23/26/23 $18.15 -0.71% 3,48,196
22/26/22 $18.28 +2.41% 2,33,948
18/26/18 $17.85 +1.48% 2,28,693
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
18.71USD
Average target price
63.75USD
Spread / Average Target
+240.73%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FBRX Stock